PMID- 35305258
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20221207
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 82
IP  - 5
DP  - 2022 Apr
TI  - Nirmatrelvir Plus Ritonavir: First Approval.
PG  - 585-591
LID - 10.1007/s40265-022-01692-5 [doi]
AB  - Nirmatrelvir plus ritonavir (Paxlovid; Pfizer) is a co-packaged combination of 
      nirmatrelvir and ritonavir tablets, intended for co-administration and developed 
      for the treatment and post-exposure prophylaxis of coronavirus disease 2019 
      (COVID-19). Nirmatrelvir is a peptidomimetic inhibitor of the severe acute 
      respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease, while ritonavir is 
      a human immunodeficiency virus type 1 (HIV-1) protease inhibitor and CYP3A 
      inhibitor. Nirmatrelvir plus ritonavir received its first conditional 
      authorization in December 2021 in the United Kingdom, for the treatment of 
      COVID-19 in adults who do not require supplemental oxygen and who are at 
      increased risk for progression to severe COVID-19. In January 2022, nirmatrelvir 
      plus ritonavir received authorization in the EU for use in the same indication. 
      Nirmatrelvir plus ritonavir is authorized for emergency use in the USA. This 
      article summarizes the milestones in the development of nirmatrelvir plus 
      ritonavir leading to its first authorizations and approval for the treatment of 
      COVID-19.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Lamb, Yvette N
AU  - Lamb YN
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. 
      dru@adis.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antiviral Agents)
RN  - O3J8G9O825 (Ritonavir)
SB  - IM
EIN - Drugs. 2022 Jun;82(9):1025. PMID: 35689762
MH  - Adult
MH  - Antiviral Agents/therapeutic use
MH  - Humans
MH  - *Ritonavir/pharmacology/therapeutic use
MH  - SARS-CoV-2
MH  - *COVID-19 Drug Treatment
PMC - PMC8933659
COIS- During the peer review process the manufacturer of the agent under review was 
      offered an opportunity to comment on the article. Changes resulting from any 
      comments received were made by the authors on the basis of scientific 
      completeness and accuracy. Yvette Lamb is a salaried employee of Adis 
      International Ltd/Springer Nature, and declares no relevant conflicts of 
      interest. All authors contributed to the review and are responsible for the 
      article content.
EDAT- 2022/03/20 06:00
MHDA- 2022/04/21 06:00
PMCR- 2022/03/19
CRDT- 2022/03/19 17:08
PHST- 2022/03/20 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2022/03/19 17:08 [entrez]
PHST- 2022/03/19 00:00 [pmc-release]
AID - 10.1007/s40265-022-01692-5 [pii]
AID - 1692 [pii]
AID - 10.1007/s40265-022-01692-5 [doi]
PST - ppublish
SO  - Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.